Literature DB >> 8017876

Establishment and use of multiple sclerosis registers--EDMUS.

C Confavreux1.   

Abstract

EDMUS, the European Database for Multiple Sclerosis, is a clinical database system for multiple sclerosis (MS) that was established on the occasion of the first European Concerted Action for MS, under the auspices of the Commission of the European Communities. Automated functions have been incorporated in the program to preserve consistency between data, generate indexes, provide classifications, and protect a patient's privacy. Retrieval of data, selection of records, and export of selected data to standard software programs are easy. The system is user-friendly, and the user is self-sufficient in all operations. The system has been available since October 1992. By August 31, 1993, it had been implemented in 58 sites. As improvements are made in current operations and new aspects of the disease described, EDMUS is updated. A connection with the North American MS-COSTAR database system for MS is underway, with support of the International Federation of the Multiple Sclerosis Societies. Several international multi-center collaborations are being developed within the framework of a new 3-year European Concerted Action entitled "Establishment and Use of EDMUS as a Database System for Multiple Sclerosis Research in Europe."

Entities:  

Mesh:

Year:  1994        PMID: 8017876     DOI: 10.1002/ana.410360733

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

1.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

2.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

3.  3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.

Authors:  Laurent Flet; Elisabeth Polard; Olivia Guillard; Emmanuelle Leray; Hervé Allain; Loïc Javaudin; Gilles Edan
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

Review 4.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

5.  Association of multiple sclerosis susceptibility variants and early attack location in the CNS.

Authors:  Ellen M Mowry; Robert F Carey; Maria R Blasco; Jean Pelletier; Pierre Duquette; Pablo Villoslada; Irina Malikova; Elaine Roger; R Phillip Kinkel; Jamie McDonald; Peter Bacchetti; Emmanuelle Waubant
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

6.  Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.

Authors:  Ellen M Mowry; Robert F Carey; Maria R Blasco; Jean Pelletier; Pierre Duquette; Pablo Villoslada; Irina Malikova; Elaine Roger; R Phillip Kinkel; Jamie McDonald; Peter Bacchetti; Emmanuelle Waubant
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

7.  Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS).

Authors:  Ellen M Mowry; Robert A Bermel; James R Williams; Tammie L S Benzinger; Carl de Moor; Elizabeth Fisher; Carrie M Hersh; Megan H Hyland; Izlem Izbudak; Stephen E Jones; Bernd C Kieseier; Hagen H Kitzler; Lauren Krupp; Yvonne W Lui; Xavier Montalban; Robert T Naismith; Jacqueline A Nicholas; Fabio Pellegrini; Alex Rovira; Maximilian Schulze; Björn Tackenberg; Mar Tintore; Madalina E Tivarus; Tjalf Ziemssen; Richard A Rudick
Journal:  Front Neurol       Date:  2020-08-07       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.